Simultaneous genotyping of three major Se enzyme inactivating SNPs of FUT2 based on a triplex probe-based fluorescence melting-curve analysis

• Published in: Clinica chimica acta 2022-05, Vol.530, p.50-54
• Main Authors: Soejima, Mikiko, Koda, Yoshiro
• Format: Article
• Language: English
• Subjects: Alleles; Asians; Eprobe; Fucosyltransferases - genetics; FUT2; Genotype; Humans; Polymorphism, Single Nucleotide; Rs1047781; Rs200157007; Rs601338; TaqMan probe
• ISSN: 0009-8981; 1873-3492
• DOI: 10.1016/j.cca.2022.03.003

•FUT2 polymorphism determines secretor status of ABH antigens and associates with susceptibility to various clinical conditions.•We developed a triplex probe-based fluorescence melting-curve analysis for genotyping of 302C>T, 385A>T, and 428G>A of FUT2.•The present triplex probe-based fluorescence melting-curve analysis is useful for large scale association studies of FUT2. The ABO(H) secretor status is controlled by FUT2-encoded α(1,2)fucosyltransferase (Se enzyme) activity. Three SNPs of FUT2, 302C>T (rs200157007), 385A>T (rs1047781), and 428G>A (rs601338), cause three major variants of nonsecretor (se) or weak-secretor (Sew) alleles. Evidence has been accumulating that suggests the secretor status is associated with various conditions including infectious diseases but a robust multiplex method for assaying relatively large-scale samples to determine the genotype of these three SNPs simultaneously has not been developed yet. By combined usage of two Eprobes and a dual-labeled fluorescence probe, we developed a real-time PCR, followed by triplex probe-based fluorescent melting-curve analysis (FMCA) for genotyping of 302C>T, 385A>T, and 428G>A of FUT2 in a single tube. Three genotypes of each of three variants of FUT2 were accurately determined by the triplex probe-based FMCA. We then validated this method using genomic DNA samples of 47 Bangladeshis, and the results obtained by using this method were fully concordant with those by previous Sanger sequencing. Since the present single triplex probe-based FMCA is robust, fast, and cost-effective, we are able to effectively estimate the secretor status of subjects on a large scale in many populations around the world.